A new Nature study found that adults with ADHD who start blood pressure medication face significantly higher rates of heart failure, stroke, and death than those without ADHD on the same drugs.
The standard model of treating multiple chronic conditions is additive: identify each problem, find the appropriate medication for each, and manage them in parallel. ADHD gets a stimulant or a non-stimulant. High blood pressure gets an antihypertensive. Each condition has its established treatment pathway, and the expectation is that managing them appropriately will produce outcomes similar to what the trials showed for each drug individually.
A nationwide cohort study published in Nature Mental Health has produced evidence that this model breaks down for adults managing both ADHD and hypertension simultaneously.
Researchers led by Yiling Zhou, Douwe Postmus, and Catharina A. Hartman at the University of Groningen in the Netherlands used data from the Netherlands to identify adults initiating antihypertensive medications and track their long-term cardiorenal illness trajectories. The analysis used multistate modeling, a statistical approach that tracks patients through multiple states of health and illness over time rather than simply measuring whether a single outcome occurred, providing a more granular picture of how disease progresses in the years after starting treatment.
The researchers separated participants into two groups based on whether they had an ADHD diagnosis and compared their long-term trajectories on every major adverse cardiorenal outcome: heart failure hospitalization, stroke, and cardiorenal death.
The findings revealed a consistent and significant gap. Adults with ADHD showed substantially higher rates of all three outcomes compared with adults without ADHD who had initiated the same blood pressure medications under otherwise comparable circumstances. The gap was not explained by differences in which antihypertensives were prescribed. It persisted after statistical adjustment for measured confounders. ADHD emerged as an independent predictor of worse long-term cardiovascular outcomes in this context.
“This study reinforces that ADHD itself, not just its pharmacologic management, may carry downstream cardiometabolic consequences,” the Psychiatric Times summary of the study noted in its review of the findings.
Why ADHD might affect cardiovascular outcomes independently
The connection between ADHD and cardiovascular risk did not begin with this study. A growing body of evidence has documented elevated rates of cardiovascular disease in adults with ADHD independent of whether they take ADHD medication.
Several mechanisms have been proposed. The first involves the dysregulation of the autonomic nervous system that is increasingly recognized as a feature of ADHD. The autonomic nervous system governs heart rate, blood pressure variability, and the balance between sympathetic activation and parasympathetic recovery. In people with ADHD, research has documented reduced heart rate variability, impaired parasympathetic tone, and patterns of autonomic dysregulation that are independently associated with adverse cardiovascular outcomes. If the cardiovascular system in ADHD operates with a different baseline pattern of stress and recovery, blood pressure medication may not normalize outcomes in the way it does when the underlying autonomic architecture is intact.
A second mechanism involves the psychological and behavioral dimensions of ADHD. Adults with ADHD face higher rates of impulsivity, stress reactivity, sleep disruption, irregular eating patterns, and difficulty maintaining consistent routines. Each of these factors independently affects cardiovascular health. When someone has ADHD and hypertension simultaneously, the cardiovascular burden may extend well beyond what a blood pressure reading captures.
A third mechanism is medication adherence. ADHD is characterized by difficulty with sustained effortful behavior, including the consistent daily routine of taking a medication that produces no immediately perceptible effect. Prior research has documented lower adherence to antihypertensive medications in adults with ADHD compared to those without, which could produce worse outcomes even when the prescription is technically appropriate. A separate multinational cohort study published in BMC Medicine in 2026, covering 12 million adults initiating antihypertensives across seven countries, found that ADHD was associated with significantly higher rates of antihypertensive medication discontinuation, with adults with ADHD 14% more likely to discontinue treatment compared to those without ADHD.
But adherence alone is unlikely to explain the full gap. The Nature Mental Health study’s use of multistate modeling to track illness trajectories, rather than simply measuring whether patients took their pills, suggests that the worse outcomes in ADHD reflect something more complex than missed doses.
What multistate modeling reveals that standard analyses miss
The methodological approach of the study is worth understanding because it changes what kind of question the research can answer.
Standard cohort studies typically measure whether a specific outcome, such as heart failure, occurred within a defined follow-up period. This approach captures whether something happened but loses information about the sequence and timing of how illness develops. A patient who developed heart failure quickly and died within a year looks statistically identical to a patient who developed it slowly and lived for another decade.
Multistate modeling tracks patients through multiple health states sequentially: from stable on medication, to first adverse event, to multiple adverse events, to death. By following these transitions across the full follow-up period, the analysis captures not just whether outcomes occurred but how quickly they occurred, in what sequence, and how each transition affected subsequent risk. This produces a richer picture of how chronic illness trajectories differ between groups.
Applied to the comparison of ADHD and non-ADHD adults on antihypertensives, multistate modeling revealed that the ADHD group was transitioning more quickly and more frequently through adverse states. This is not simply a matter of having more bad outcomes; it is a fundamentally different illness trajectory, one in which the progression from initiated treatment to hospitalization to serious disease moved at a faster pace in the ADHD group.
This finding has direct implications for clinical monitoring. If adults with ADHD follow a faster trajectory toward adverse cardiovascular outcomes after initiating antihypertensive treatment, the monitoring protocols designed for the average hypertensive patient may be insufficient for this subgroup.
Who is affected and why it matters
The intersection of ADHD and hypertension is not rare. ADHD affects an estimated 4 to 5 percent of adults globally, with prevalence estimates suggesting that somewhere between 100 and 180 million adults worldwide currently meet diagnostic criteria. Hypertension affects approximately 1.3 billion adults globally and is the leading modifiable risk factor for cardiovascular disease and death. At the population level, tens of millions of adults worldwide have both conditions simultaneously.
The concern raised by this study is that those adults may be receiving a treatment protocol designed for the average hypertensive patient, applied to a population with a meaningfully different underlying cardiovascular risk trajectory. The same blood pressure medication, prescribed at the same dose, monitored with the same frequency, may produce outcomes that diverge substantially depending on whether the patient also has ADHD.
This is the precise scenario in which the additive model of treating multiple conditions breaks down. Managing each condition separately, with separate specialists and separate follow-up schedules, may miss the interaction between them that this study has now documented.
The study also adds a specific dimension to the growing literature on ADHD as a condition with whole-body health consequences beyond its neurological presentation. Over the past decade, research has documented elevated rates in adults with ADHD of obesity, type 2 diabetes, sleep disorders, substance use, and now worse cardiovascular outcomes in the context of treated hypertension. The picture that is emerging is of ADHD as a condition that affects multiple organ systems and multiple health trajectories, not simply a neurodevelopmental disorder managed by a psychiatrist.
What this means for clinical practice
The most immediate clinical implication is that cardiovascular monitoring in adults with ADHD who develop hypertension may need to be more intensive than for hypertensive patients without ADHD.
Standard antihypertensive management typically involves follow-up at intervals of three to six months once a patient is stable on a regimen, with annual comprehensive review. If adults with ADHD are progressing through adverse illness states more quickly, those intervals may be insufficient to detect and respond to deterioration before it reaches hospitalization level.
A secondary implication concerns the prescription of antihypertensive medications themselves. ADHD stimulant medications, specifically amphetamines and methylphenidate, elevate heart rate and blood pressure as a known side effect. For an adult who already has hypertension, the interaction between the ADHD medication and the antihypertensive requires more careful management than either drug would require alone. Which antihypertensive agents are most appropriate for adults also taking ADHD stimulants, and at what doses, is a question that standard prescribing guidance does not fully address.
The third implication involves adherence support. If a meaningful portion of the worse outcomes in adults with ADHD on antihypertensives reflects lower medication adherence, then adherence support strategies tailored to the cognitive and behavioral profile of ADHD could reduce some of the excess risk. Simpler dosing schedules, automated reminders, and adherence monitoring built into routine clinical contact are all strategies with an evidence base in other populations that have not been specifically applied to the ADHD plus hypertension intersection.
What the study does not establish
The study is observational and relies on registry data from the Netherlands, which limits both causal interpretation and direct generalizability to other healthcare systems and populations with different demographics, prescribing cultures, and access to care.
The multistate modeling approach, while methodologically sophisticated, cannot rule out residual confounding from unmeasured factors that differ between adults with and without ADHD and that also affect cardiovascular outcomes. Socioeconomic status, lifestyle factors, psychiatric comorbidities, and substance use all differ between the populations and all affect cardiovascular risk in ways that are difficult to fully capture in administrative health data.
The study does not report the specific magnitude of each outcome difference in a form that can be directly quoted without access to the full paper. The finding is described in the literature as showing “significantly higher rates” across all outcomes, without a specific overall risk multiplier being available from the summary sources that can be independently verified.
What the study establishes clearly is the pattern: across multiple adverse cardiovascular outcomes and across the illness trajectory modeled over time, adults with ADHD who initiate antihypertensive treatment fare significantly worse than adults without ADHD on the same treatment. That pattern is consistent with other recent data on ADHD and cardiovascular risk and extends it into the specific and clinically important context of treated hypertension.
The study, “Long-term cardiorenal illness trajectories after initiation of antihypertensive medications in adults with and without ADHD: a nationwide cohort study”, was authored by Yiling Zhou, Douwe Postmus, and Catharina A. Hartman at the University Medical Center Groningen and affiliated institutions, and published August 31, 2026 in Nature Mental Health.
Source: University of Groningen / Nature Mental Health. DOI: 10.1038/s44220-026-00718-1
